7B3O

Crystal structure of the SARS-CoV-2 RBD in complex with STE90-C11 Fab

Summary for 7B3O

• Entry DOI: 10.2210/pdb7b3o/pdb
• Descriptor: Spike protein S1, Light Chain of Fab Fragment, Heavy Chain of Fab Fragment, ... (5 entities in total)
• Functional Keywords: neutralizing antibodies, sars-cov-2, rbd, antiviral protein
• Biological source: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2); More
• Total number of polymer chains: 3
• Total formula weight: 71075.34

Authors

Kluenemann, T.,Van den Heuvel, J. (deposition date: 2020-12-01, release date: 2020-12-16, Last modification date: 2024-11-13)

Primary citation

Bertoglio, F.,Fuhner, V.,Ruschig, M.,Heine, P.A.,Abassi, L.,Klunemann, T.,Rand, U.,Meier, D.,Langreder, N.,Steinke, S.,Ballmann, R.,Schneider, K.T.,Roth, K.D.R.,Kuhn, P.,Riese, P.,Schackermann, D.,Korn, J.,Koch, A.,Chaudhry, M.Z.,Eschke, K.,Kim, Y.,Zock-Emmenthal, S.,Becker, M.,Scholz, M.,Moreira, G.M.S.G.,Wenzel, E.V.,Russo, G.,Garritsen, H.S.P.,Casu, S.,Gerstner, A.,Roth, G.,Adler, J.,Trimpert, J.,Hermann, A.,Schirrmann, T.,Dubel, S.,Frenzel, A.,Van den Heuvel, J.,Cicin-Sain, L.,Schubert, M.,Hust, M.
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.
Cell Rep, 36:109433-109433, 2021

PubMed Abstract: The novel betacoronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causes a form of severe pneumonia disease called coronavirus disease 2019 (COVID-19). To develop human neutralizing anti-SARS-CoV-2 antibodies, antibody gene libraries from convalescent COVID-19 patients were constructed and recombinant antibody fragments (scFv) against the receptor-binding domain (RBD) of the spike protein were selected by phage display. The antibody STE90-C11 shows a subnanometer IC in a plaque-based live SARS-CoV-2 neutralization assay. The in vivo efficacy of the antibody is demonstrated in the Syrian hamster and in the human angiotensin-converting enzyme 2 (hACE2) mice model. The crystal structure of STE90-C11 Fab in complex with SARS-CoV-2-RBD is solved at 2.0 Å resolution showing that the antibody binds at the same region as ACE2 to RBD. The binding and inhibition of STE90-C11 is not blocked by many known emerging RBD mutations. STE90-C11-derived human IgG1 with FcγR-silenced Fc (COR-101) is undergoing Phase Ib/II clinical trials for the treatment of moderate to severe COVID-19.

PubMed: 34273271
DOI: 10.1016/j.celrep.2021.109433

Experimental method

X-RAY DIFFRACTION (2 Å)